CN114656417A - Synthesis method and application of chiral oxazoline - Google Patents
Synthesis method and application of chiral oxazoline Download PDFInfo
- Publication number
- CN114656417A CN114656417A CN202210366119.5A CN202210366119A CN114656417A CN 114656417 A CN114656417 A CN 114656417A CN 202210366119 A CN202210366119 A CN 202210366119A CN 114656417 A CN114656417 A CN 114656417A
- Authority
- CN
- China
- Prior art keywords
- oxazoline
- chiral
- synthesis
- compound
- synthesis method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/12—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
[1,4- (4S/R) -di (R) -2-oxazoline group]Benzene [ R: CH (CH)3)2,CH2Ph]The synthesis method comprises the step of synthesizing a target macromolecular palladium complex Pd [ R: CH (CH)3)2,CH2Ph]Firstly reacting with silver trifluoromethanesulfonate or silver nitrate, then reacting with alkali such as amino alcohol, bipyridine or triethylamine, and decomposing the complex to obtain chiral oxazoline ligand compounds I and II, wherein the structural formulas are as follows:R:I:L‑CH(CH3)2II:D‑CH2use of Ph of the chiral oxazoline compound II in the preparation of an anti-cancer agent, which shows inhibitory activity in the human breast cancer cell MCF-7 assay as an anti-cancer agent.
Description
One, the technical field
The invention relates to a method for synthesizing a chiral compound, in particular to a method for synthesizing a compound containing chiral oxazoline groups.
Second, background Art
Chiral oxazoline and metal complexes have been drawing attention because they exhibit good asymmetric catalytic activity and high enantioselectivity in a number of reactions such as Didls-Alder (Diels-Alder) diene cycloaddition reaction, Michael condensation reaction, Friedel-Crafts condensation reaction, Aldol reaction, Henry reaction, nitrile silicification and the like [1-4 ].
(1)(a)Glos,M.;Reiser,O.Org.Lett.2000,2(14),2045.(b)Braga,A.L.Vargas,F.; Sehnem,J.A.;Braga,R.C.J.Org.Chem.2005,70(22),9021.(c)Breit,B.;Schmidt,Y.; Chem.Rev.2008,108(8),2928.(d)McManus,H.A.;Guiry,P.J.J.Org.Chem.2002,67(24), 8566.
(2)Wang,W.B.;Fang,J.M.J.Org.Chem.1998,63,1356.
(3)(a)Fu,G.C.Acc.Chem.Res.2006,39(11),853.(b)Hargaden,G.C.;Patrick J.Guiry, P.J.Chem.Rev.2009,109(6),2505.(c)McManu,H.A.;Guiry,P.J.Chem.Rev.2004,104(9), 4151.
(4)(a)Takamichi,Y.;Masatoshi,O.;Takahiro,K.;Dai,M.;Kiyoshi,S.;Motowo, Y.Tetrahedron:Asymmetry 2003,14,3275.(b)Cristina G.-Y.,P.J.;Frank R.; Günter,H.Organometallics 2004,23,5459.(c)Delphine,F.;Montserrat,G.,Francisco, J.,Guillermo,M.;Mercè,R.,Miguel,A.M.,;José,M.Organometallics 2004,23(13), 3197.(d)Koch,G.;Guy,C.;Loiseleur,O.;Pfaltz,A.;Pretot,R.;Schaffner,S.; Schnider,P.;Von Matt,P.Recueil des Travaux Chimiques des Pays-Bas 1995,114(4/5), 206.(e)Sprinz,J.;Helmchen,G.Tetra.Lett.1993,34(11),1769.(f)Franco,D.;Gomez, M.;Jimenez,F.;Muller,G.;Rocamora,M.;Maestro,M.A.;Mahia,J.Organometallics 2004,23(13),3197。
The applicant has long worked on the development of asymmetric compounds and successively applied for patent applications, zl200610096004.x, CN101016311A, CN101099936A, 200810020198.4, CN101279954A, 200810022278.3 and 200910116614.5.
Third, summary of the invention
The invention aims to provide a synthesis method for the field of asymmetric synthesis, in particular for preparing chiral pharmaceutical compounds, and solves the technical problem of one-step synthesis of ligand oxazoline by selecting a metal complex.
The chiral oxazoline compound is prepared from palladium complex [ R: CH (CH)3)2]With silver triflate or silver nitrate and then with a base such as aminoalcohol, bipyridine or triethylamine to give the following chemical names: [1,4- (4S) -diisopropyl-2-oxazolinyl group]Benzene, its chemical formula is as follows:
the chiral oxazoline compound II is prepared from palladium complex [ R: CH2Ph]With silver triflate or silver nitrate and then with a base such as aminoalcohol, bipyridine or triethylamine to give the following chemical names: [1,4- (4R) -dibenzyl-2-oxazoline group]Benzene, its chemical formula is as follows:
the chiral compound is synthesized by using target macromolecular palladium complex Pd [ R: CH (CH)3)2]And Pd [ R: CH2Ph]Firstly reacting with silver trifluoromethanesulfonate or silver nitrate, then reacting with alkali such as amino alcohol, bipyridine or triethylamine, and decomposing the complex to obtain the chiral oxazoline ligand compound. The flow is shown as follows:
the R group: the L-valinol is selected from D-phenylalaninol.
The compound has already filed a chinese patent in 2010: a chiral oxazoline and a synthetic method thereof. Application No.: 2010105600901. At present, the compound II is found to show a certain inhibiting effect in anti-tumor human breast cancer cells (MCF-7), and the index IC50 value reaches 8.24 +/-0.11.
Description of the drawings
1. FIG. 1 is a nuclear magnetic structural hydrogen spectrum of a target compound I.
2. FIG. 2 is a nuclear magnetic structure carbon spectrum diagram of the target compound I.
3. FIG. 3 is a nuclear magnetic structural hydrogen spectrum of the objective compound II.
2. FIG. 4 is a nuclear magnetic structure carbon spectrum of the target compound II.
Fifth, detailed description of the invention
Preparation of (I) chiral Compound 1
1. Process for the preparation of chiral compound 1
0.2240g of L-palladium complex (the synthesis method is shown in Chinese patent: chiral bis-oxazoline palladium complex crystal and synthesis method; application number: 2015102587058) and 0.7g of silver trifluoromethanesulfonate are dissolved in dichloromethane solution under anhydrous and anaerobic conditions, and 0.8251g of L-valinol and 1.0mL of triethylamine are added, or 0.1000g of bipyridine is added. The reaction solution immediately became clear. After 48 hours of reflux, the reaction was stopped. Hot filtering, and naturally volatilizing to obtain 0.1240g of crystals; yield: 85 percent; m.p.48-50 ℃; [ alpha ] to]25 D=-111.9°(c=0.429,CHCl3);1H NMR(600MHz,298K,CDCl3)δppm 7.97(s, 4H,ArH),4.40(t,J=8.1Hz,2H,CH×2),4.10-4.15(m,4H,CH2×2),1.85-1.88(m, 2H,CH×2),1.03(d,J=6.0Hz,6H,CH3×2),0.94(d,J=6.0Hz,6H,CH3×2);13C NMR(150MHz,298K,CDCl3)δppm 162.8,130.3,128.1,72.8,70.2,32.8,18.9,18.1 (×2);HRMS(EI)m/z(%)calcd.for C18H24N2O2 300.1838;found 300.1833.νmax(cm-1) 3273,2976,2960,2932,2889,2869,1643,1512,1469,1408,1382,1366,1350,1320, 1296,1276,1214,1180,1108,1077,1047,1014,971,955,900,891,838,726,698, 675,659,540。
2. Preparation method of chiral compound II
0.0325g of D-palladium complex (see the synthesis method in the specification) under anhydrous and oxygen-free conditionsThe national patent discloses a chiral oxazoline palladium complex crystal and application thereof; application No.: 202210290030.5) and 0.2g of silver trifluoromethanesulfonate in 30mL of dichloromethane, and adding 0.8251g of D-phenylglycinol and 2.0mL of triethylamine, the reaction solution becomes clear immediately. After 48 hours of reflux, the reaction was stopped. Hot filtering, and naturally volatilizing to obtain 0.0135g of crystal and yield; 88 percent; [ alpha ] of]25 D=+39.1°(c 0.098,CHCl3);1H NMR(500MHz,298K,CDCl3)δppm 7.98(s,4H),7.22-7.32(m,10H,ArH),4.59-4.61 (m,2H,CH×2),4.37(t,J=8.9Hz,2H,CH×2),4.16(t,J=7.9Hz,2H,CH×2),3.23, 3.26(dd,J=5.1,5.1Hz,2H,CH×2),2.71,2.75(dd,J=9.0,9.0Hz,2H,CH2× 2);13C{1H}NMR(125MHz,298K,CDCl3)163.4,137.8,130.2,129.2,128.6,128.2,126.6, 72.0,68.0,41.8;HRMS(EI)m/z(%)calcd for C26H24N2O2 396.1838;found 396.1833.νmax(cm-1)3420,3081,3054,3031,2988,2956,2893,2231,1647,1608,1497,1454,1406, 1359,1343,1317,1293,1276,1262,1201,1174,1073,1046,1017,967,953,860,840, 755,697,669,548,527。
Application of (II) chiral compound II in resisting tumor breast cancer
The compound (I) designed and synthesized according to the target shows stronger inhibitory activity (ED50 < 10.0 mu g/mL) in the test of breast cancer cells (MCF-7). Reference [ j.natl.cancer inst.1990, 82 (13): 1107-1112]The test was carried out by the method described in (1). Briefly, human cancer cells (DU145, PC-3, A549, KB, KB-VIN, etc.) used were placed in a single medium (RPMI-1640 containing 10% (v/v) calf serum), and morphological characteristics and growth conditions of the cells in the culture were examined with a microscope. The cells were placed at 2.5cm2The culture dish was incubated at 37 ℃ in a humidified atmosphere containing 5% CO 2. The cell lines grow adherently. The process of sample preparation and dilution and inoculation into the cell fluid should be aseptic. The test samples were typically dissolved in DMSO and stored at-70 ℃. In a 96 well culture plate, each well was placed at different concentrations of test sample and approximately 5000-. IC50 values for inhibition of cancer cell growth by SRB (sulfoformaldehyde B)And (4) determining the method. The results of some of the anti-cancer activity tests of the compounds of the present invention are shown in table 1.
TABLE 1 anticancer Activity data (IC50 values) of (I)
The IC50 is the effective concentration to inhibit growth of half of the cancer cells, indicating anti-cancer activity. The unit is μ M; NA: has no inhibitory activity. The human cancer cells used in this experiment were purchased from ATCC in the United states.
Claims (3)
1. [1,4- (4S) -diisopropyl-2-oxazoline group shown in the following chemical formula (I)]The synthesis method of the benzene comprises synthesis, separation and purification, wherein the synthesis is to synthesize a target macromolecular palladium complex Pd [ R: CH (CH)3)2]Firstly reacting with silver trifluoromethanesulfonate or silver nitrate, then reacting with alkali such as amino alcohol, bipyridine or triethylamine, and decomposing the complex to obtain a chiral oxazoline ligand compound I, wherein the structural formula of the chiral oxazoline ligand compound I is as follows:
2. [1,4- (4R) -dibenzyl-2-oxazoline group shown in the following chemical formula (II)]The synthesis method of benzene comprises synthesis, separation and purification, wherein the synthesis is to synthesize the target macromolecular palladium complex Pd [ R: CH2Ph]With silver triflate or silver nitrate and then with a base such as aminoalcohol, bipyridine or triethylamine to give the following chemical names: [1,4- (4R) -dibenzyl-2-oxazoline group]Benzene, its chemical formula is as follows:
3. use of a chiral oxazoline compound II in the preparation of an anti-cancer agent, which is useful as an anti-cancer agent showing inhibitory activity in a human breast cancer cell MCF-7 assay.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210366119.5A CN114656417B (en) | 2022-04-08 | 2022-04-08 | Synthesis method and application of chiral oxazoline |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210366119.5A CN114656417B (en) | 2022-04-08 | 2022-04-08 | Synthesis method and application of chiral oxazoline |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114656417A true CN114656417A (en) | 2022-06-24 |
CN114656417B CN114656417B (en) | 2023-10-13 |
Family
ID=82034781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210366119.5A Active CN114656417B (en) | 2022-04-08 | 2022-04-08 | Synthesis method and application of chiral oxazoline |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114656417B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10324671A (en) * | 1997-05-23 | 1998-12-08 | Seikagaku Kogyo Co Ltd | Aminoalcohol derivative and pharmaceutical containing the same |
WO2000006556A1 (en) * | 1998-07-27 | 2000-02-10 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
WO2010138686A1 (en) * | 2009-05-29 | 2010-12-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mdri-inverse agents |
US20140213623A1 (en) * | 2008-06-16 | 2014-07-31 | Gtx, Inc. | Compounds for treatment of cancer |
CN104876970A (en) * | 2015-05-20 | 2015-09-02 | 罗梅 | Chiral bisoxazoline palladium complex crystal and synthesis method thereof |
CN110305167A (en) * | 2019-06-18 | 2019-10-08 | 合肥工业大学 | A kind of preparation and purposes of chirality platinum complex |
CN112755025A (en) * | 2021-01-22 | 2021-05-07 | 中国科学技术大学 | Anticancer drug, anticancer drug composition, and preparation method and application thereof |
-
2022
- 2022-04-08 CN CN202210366119.5A patent/CN114656417B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10324671A (en) * | 1997-05-23 | 1998-12-08 | Seikagaku Kogyo Co Ltd | Aminoalcohol derivative and pharmaceutical containing the same |
WO2000006556A1 (en) * | 1998-07-27 | 2000-02-10 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
US20140213623A1 (en) * | 2008-06-16 | 2014-07-31 | Gtx, Inc. | Compounds for treatment of cancer |
WO2010138686A1 (en) * | 2009-05-29 | 2010-12-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mdri-inverse agents |
CN104876970A (en) * | 2015-05-20 | 2015-09-02 | 罗梅 | Chiral bisoxazoline palladium complex crystal and synthesis method thereof |
CN110305167A (en) * | 2019-06-18 | 2019-10-08 | 合肥工业大学 | A kind of preparation and purposes of chirality platinum complex |
CN112755025A (en) * | 2021-01-22 | 2021-05-07 | 中国科学技术大学 | Anticancer drug, anticancer drug composition, and preparation method and application thereof |
Non-Patent Citations (3)
Title |
---|
LUO MEI,ET AL.: "Modular Synthesis of Oxazolines and Their Derivatives", 《J. COMB. CHEM.》, vol. 11, pages 220 - 227 * |
MEI LUO,ET AL.: "Palladium (II), platinum (II) and silver (I) complexes with oxazolines: Their synthesis, characterization, DFT calculation, molecular docking and antitumour effects", 《JOURNAL OF INORGANIC BIOCHEMISTRY》, vol. 239, pages 112048 * |
S. Ø. SCOTTWELL,ET AL.: "5-Ferrocenyl-2,20-bipyridine ligands: synthesis, palladium(II) and copper(I) complexes, optical and electrochemical properties", 《RSC ADV.》, vol. 4, pages 35726 - 35734 * |
Also Published As
Publication number | Publication date |
---|---|
CN114656417B (en) | 2023-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106831550A (en) | A kind of optical activity two(It is miscellaneous)Aryl methyl alcohol and its method of asymmetric synthesis | |
CN115385916B (en) | Chiral indoline pyrrole compound and synthesis method thereof | |
CN114656417B (en) | Synthesis method and application of chiral oxazoline | |
Maples et al. | Hydrogen-1 nuclear magnetic resonance studies of the formation and decarbonylation of diphosphine-substituted acetylmanganese tricarbonyl complexes | |
CN110642677B (en) | Preparation of diaryl derivative, diaryl derivative and application | |
CN113546085B (en) | Application of chiral diphosphonic diamide compound | |
Darby et al. | The preparation of 4 (5)-hydroxymethyl-imidazole | |
CN111196791B (en) | Chiral gamma-butyrolactone derivative and synthesis method and application thereof | |
Grassi et al. | Synthesis of (+)-(3S, 7S, 10S)-and (+)-(3S, 7S, 10R)-3, 7, 10-trimethylboratrane. Amplification of enantiomeric purity in the reacti | |
CN111675736B (en) | Rhodium complex containing ortho-carborane Schiff base ligand and preparation method and application thereof | |
CN111004145B (en) | Chiral optical amide substituted alpha, beta-diamino acid derivative and preparation method and application thereof | |
CN110483465B (en) | Synthesis method of genistein bridged piperazine derivatives and application of genistein bridged piperazine derivatives in anti-tumor direction | |
EP0220887A1 (en) | Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound | |
CN107759619B (en) | Dihydropyrano-thiazole ring compound and preparation method and application thereof | |
CN105367445B (en) | Preparation, structure and application of benzyl dihydrazone-N-mono-(2-hydroxy-4-diethylin-1-formyl benzene) | |
RU2751352C1 (en) | Substituted (e)-9-azabicyclo[4.2.1]nona-2,4-dienes, method for their preparation and use as anticancer drugs | |
CN111892486B (en) | Hydroxyl-substituted benzophenone compound and preparation method and application thereof | |
CN102702120A (en) | New compound o-hydroxyphenyl tetrazine dicarbonamide, preparation and application thereof | |
CN114891046B (en) | Tri-discoene metallocene catalyst and application thereof | |
CN115850170A (en) | Acridine-10 (9H) - (3, 4, 5-trimethoxyphenyl) ketone compound and preparation method and application thereof | |
RU2746853C1 (en) | Substituted 9-azabicyclo [4.2.1] nona-2,4,7-trienes, method for their preparation and application as antitumor activities | |
CN105367446B (en) | The structure of benzil dihydrazone N, N ' double (2 hydroxyl, 5 chlorine, 1 formoxyl benzene), preparation and use | |
US3299141A (en) | Nu-hydroxyalkyl-nu-alkynyl-nu-alkyl-and aralkyl amines and process for the preparation thereof | |
CN109232539B (en) | Bis-quinazoline Schiff base derivatives with anticancer activity and preparation and medical application thereof | |
KR820000181B1 (en) | Process for preparing carbamoyl piperazine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |